
Give the Gift of Choice!
Too many options? Treat your friends and family to their favourite stores with a Bayshore Shopping Centre gift card, redeemable at participating retailers throughout the centre. Click below to purchase yours today!Purchase HereHome
Making the Case for MTET: Where Miracles Become Standard In Oncology
Coles
Loading Inventory...
Making the Case for MTET: Where Miracles Become Standard In Oncology in Ottawa, ON
By None
Current price: $300.21


By None
Making the Case for MTET: Where Miracles Become Standard In Oncology in Ottawa, ON
Current price: $300.21
Loading Inventory...
Size: Hardcover
*Product information may vary - to confirm product availability, pricing, shipping and return information please contact Coles
Millions of cancer cases are diagnosed yearly. While a cure has yet to be discovered, one of the most promising new treatments is Multi-Targeted Epigenetic Therapy, or MTET.
In Making the Case for MTET , world-renowned oncology expert Dr. Mohammad A. Nezami introduces his revolutionary method of treating patients with advanced cancer by using a careful combination of drugs and genomic sequencing. For some patients with stage four cancer, MTET has been a lifesaving intervention. Dr. Nezami presents 300 case studies of patients with advanced cancer that he treated over ten years of longitudinal tracking with MTET. Through meticulously documented data, lab reports, and full-color photographs to detailed genomic information, Dr. Nezami makes a compelling case for furthering MTET research and focusing on patient-centric care.
Millions of cancer cases are diagnosed yearly. While a cure has yet to be discovered, one of the most promising new treatments is Multi-Targeted Epigenetic Therapy, or MTET.
In Making the Case for MTET , world-renowned oncology expert Dr. Mohammad A. Nezami introduces his revolutionary method of treating patients with advanced cancer by using a careful combination of drugs and genomic sequencing. For some patients with stage four cancer, MTET has been a lifesaving intervention. Dr. Nezami presents 300 case studies of patients with advanced cancer that he treated over ten years of longitudinal tracking with MTET. Through meticulously documented data, lab reports, and full-color photographs to detailed genomic information, Dr. Nezami makes a compelling case for furthering MTET research and focusing on patient-centric care.

















